Chronic Subdural Hematoma Recurrence (cSDH RCT)
The Effect of Dextrose 5% in 0.225% Sodium Chloride (D5 ¼NS) on Postoperative Chronic Subdural Hematoma Size and Recurrence Rate: a Prospective, Randomized, Double-blinded, Placebo Controlled Clinical Trial
How can investigators improve recurrence rates of chronic subdural hematomas to reduce need for surgical intervention? Study investigators hypothesize that Dextrose 5% in 0.225% Sodium Chloride (D5 ¼NS) will increase the intracellular brain volume and water content post-operatively, reducing the residual subdural space that is created by evacuation of the chronic subdural hematoma (CSDH), and that this, in turn, will reduce the hematoma volume that will then potentially lead to improved functional outcomes, reduced hospitalization time as well as the reduced rate of symptomatic recurrence requiring redo surgery.
研究概览
详细说明
The proposed study is a randomized, placebo controlled clinical trial to investigate the effects of D5 ¼NS (treatment) vs. NS (placebo) on residual cSDH volume after surgical drainage via a craniotomy or burr holes.
Participants in the study will be adult patients who had presented with imaging evidence (based on non-contrast head CT) of cSDH requiring surgical evacuation (craniotomy or burr holes). Patients in this study will receive either 5% dextrose ¼Normal Saline (treatment) or Normal Saline (placebo) for 24h after surgery. The study group assignment will be performed based on randomization process prior to the surgery. All the patients will be undergoing a head CT without contrast imaging at 24h after surgery. The residual hematoma volume will be calculated based on XYZ/2 method as previously described (Sucu et al., 2005).
The bedside nursing staff will be provided with either the placebo or D5 ¼NS solutions from the pharmacy in an opaque bag to be administered to the patient after the randomization process has taken place. The procedure for the placebo and treatment solution administration is the same as the standard intravenous fluid administration procedure except the fact of an opaque covering and maintenance of the blinding throughout the process. The bedside nursing staff will administer the intravenous fluid. The infusion rate, as stated, will be 100 cc/h for 24h after SDH evacuation surgery at which time a standard of care head CT without contrast will be obtained. This will be a double-blinded study where blinding will be achieved via the prerandomized enrollment log. Participants signing the consent will be enrolled based on time of enrollment and study ID will be prelinked to a study group of normal saline (placebo) or D51/4NS solution. Pharmacy who will be documenting the treatment allocation and will be issuing the IV fluid for each of the patients will be maintaining the blinding status. The pharmacy staff and coordinator will be the only individuals holding the blinding key which will be released at the official end of the study after all the datapoints have been gathered for all the participants. Additionally, the patients will have basic metabolic panel (BMP as standard of care ) labs drawn every 12 hours during the 24 hour treatment period to assess the electrolyte status and any adverse reactions. The PI and all other study team members, other than the randomizing coordinator, will remain blinded. The unblinded coordinator will not perform any clinical assessments and will not share blinding information with any other team members.
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery will be identified via the chart review of each individual study participant.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Jordan Darden, PhD
- 电话号码:540-529-7792
- 邮箱:jadarden@carilionclinic.org
研究联系人备份
- 姓名:Kristine Ravina, MD
- 电话号码:540-224-5170
- 邮箱:kravina@carilionclinic.org
学习地点
-
-
Virginia
-
Roanoke、Virginia、美国、24014
- 招聘中
- Carilion Clinic
-
接触:
- Jordan Darden, PhD
- 电话号码:540-529-7792
- 邮箱:jadarden@carilionclinic.org
-
首席研究员:
- Eric Marvin, DO
-
接触:
- Kristine Ravina, MD
- 电话号码:540-224-5170
- 邮箱:kravina@carilionclinic.org
-
副研究员:
- Kristine Ravina, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Written and voluntarily given informed consent
- If the patient cannot give informed consent, a legally authorized representative may provide it
- Male or female 18-100
- Imaging evidence indicative of cSDH
- The neurosurgical team has determined that the patient requires surgical evacuation of the cSDH
Exclusion Criteria:
- significant/symptomatic hyperglycemia; specifically diabetic ketoacidosis or fasting blood glucose level >200 mg/dl
- Patients with significant hyponatremia (Na <130 mEq/L)
- Patients who are judged by investigators as being ineligible for participation in the study Patients with a history of relevant drug hypersensitivity Patients who receive another investigational drug shortly before acquisition of consent Women who are pregnant or breastfeeding
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:normal saline
normal saline |
normal saline
其他名称:
|
|
有源比较器:saline with dextrose (D5 ¼NS solutions)
saline with dextrose (D5 ¼NS solutions) |
D5 ¼NS solutions
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Comparative residual CSDH volume (in mm3) measured and calculated using head CT
大体时间:24 hours after surgery
|
Comparative residual CSDH volume (in mm3) measured and calculated using head CT |
24 hours after surgery
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
ICU and overall hospitalization length of stay
大体时间:duration of total hospital stay assessed for up to 6 months
|
ICU and overall hospitalization length of stay. |
duration of total hospital stay assessed for up to 6 months
|
|
Functional improvement as measured using mRS scale scores upon admission
大体时间:follow up post surgery assessment up to 6 weeks post release
|
Functional improvement as measured using mRS scale scores upon admission, scoring from 0-6, low score with no symptoms and 6 indicating death |
follow up post surgery assessment up to 6 weeks post release
|
|
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery
大体时间:90 days post surgery
|
Symptomatic recurrence rates requiring redo surgery within a 90-day period (+/- 7 days) after the initial surgery |
90 days post surgery
|
合作者和调查者
调查人员
- 首席研究员:Eric Marvin, DO、Carilion Clinic
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IRB-23-2036
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.